Celgene to acquire Avila Therapeutics

Thursday 26 January 2012

Celgene Corp said it has reached agreement to acquire venture-capital backed Avila Therapeutics Inc for $350 million in cash, plus milestones, thereby strengthening its position in the area of haematologic cancers.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States